Zhang C, Wu Z, Li JW, Zhao H, Wang GQ (May 2020). "Cytokine launch syndrome in intense COVID-19: interleukin-6 receptor antagonist tocilizumab may be the crucial to lessen mortality". Depending on the form of tumor, paraneoplastic phenomena - signs or symptoms not because of to the local presence of most cancers - may well initially entice attention to the illness.